Headlines about Cytosorbents (NASDAQ:CTSO) have trended positive recently, Accern reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cytosorbents earned a media sentiment score of 0.30 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 44.1224011816615 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news headlines that may have effected Accern’s analysis:
Shares of Cytosorbents (NASDAQ CTSO) traded up $0.20 during trading on Friday, reaching $7.80. 176,874 shares of the company’s stock traded hands, compared to its average volume of 126,865. The stock has a market capitalization of $218.05, a price-to-earnings ratio of -24.38 and a beta of -0.54. Cytosorbents has a one year low of $3.30 and a one year high of $7.85. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.36 and a quick ratio of 3.17.
A number of research firms recently weighed in on CTSO. Maxim Group set a $12.00 target price on shares of Cytosorbents and gave the stock a “buy” rating in a research note on Monday, January 8th. ValuEngine lowered shares of Cytosorbents from a “hold” rating to a “sell” rating in a research note on Friday, December 15th. HC Wainwright restated a “buy” rating and set a $13.00 target price on shares of Cytosorbents in a research note on Tuesday, September 26th. Finally, B. Riley restated a “buy” rating and set a $11.25 target price on shares of Cytosorbents in a research note on Friday, November 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Cytosorbents has an average rating of “Buy” and an average target price of $10.60.
In other Cytosorbents news, CFO Kathleen P. Bloch sold 32,400 shares of the stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $7.30, for a total value of $236,520.00. Following the transaction, the chief financial officer now directly owns 248,638 shares in the company, valued at $1,815,057.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Vincent Capponi sold 4,000 shares of the stock in a transaction that occurred on Monday, November 27th. The shares were sold at an average price of $7.00, for a total transaction of $28,000.00. Following the completion of the transaction, the chief operating officer now owns 271,062 shares in the company, valued at $1,897,434. The disclosure for this sale can be found here. Corporate insiders own 5.60% of the company’s stock.
WARNING: “Favorable Press Coverage Somewhat Unlikely to Affect Cytosorbents (CTSO) Stock Price” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/13/favorable-press-coverage-somewhat-unlikely-to-affect-cytosorbents-ctso-stock-price.html.
Cytosorbents Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.